Fenofibrate tablets (Lipidil) are a lipid-lowering medication primarily used to reduce triglycerides and are suitable for patients with primary hyperlipidemia. It regulates lipoprotein metabolism by activating PPAR α receptors, and strict adherence to usage and dosage, as well as attention to relevant contraindications, is necessary to ensure efficacy and safety.

Core Information of Fenofibrate Tablets (Lipidil)

1. Pharmacological effects

Fenofibrate is a type of blood lipid lowering drug that activates peroxisome proliferator activated receptor alpha (PPAR alpha), significantly reducing plasma triglyceride levels (by 30-50%) and increasing high-density lipoprotein cholesterol (HDL-C) by approximately 10-30%.

2. Indications

(1) The first-line treatment for primary hypertriglyceridemia (type IV hyperlipidemia).

(2) Adjuvant therapy for mixed hyperlipidemia (IIb type) is particularly suitable for patients with predominantly elevated triglycerides.

Usage and dosage specifications

1. Conventional dosage

The standard dose for adults is 200mg once daily, and it is recommended to take it with meals to improve bioavailability. Food can increase absorption by 20-35% while reducing gastrointestinal irritation symptoms.

2. Adjustment for special populations

(1) Renal insufficiency: moderate damage (creatinine clearance rate 30-80mL/min) requires a reduction to 67mg/day; Serious damage (<30mL/min) is prohibited.

(2) Elderly: No routine adjustments are needed, but kidney function needs to be monitored.

Important precautions

1. Contraindications

(1) Patients with severe liver and kidney dysfunction are prohibited from using it.

(2) Patients with active gallbladder disease or gallstones are prohibited from using it.

(3) Prohibited during pregnancy, lactation, and childhood.

2. Monitoring requirements

(1) Regularly monitor liver function (ALT/AST), creatine kinase (CK), and blood lipid levels before and during treatment.

(2) If symptoms such as muscle pain and weakness occur, CK should be checked immediately to rule out muscle disease.

Drug interactions

1. High risk interactions

(1) Warfarin: enhances anticoagulant effect, INR needs to be monitored and dosage adjusted.

(2) Statins: increase the risk of rhabdomyolysis, avoid combination therapy or closely monitor.

2. Other interactions

(1) Bile acid binding resin: It should be taken every 2 hours to avoid decreased absorption.

(2) Cyclosporine: May increase nephrotoxicity, should be avoided in combination.